- Home
- ELDN vs TLSA Comparison
ELDN vs TLSA Comparison
Compare ELDN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- TLSA
- Stock Information
- Founded
- ELDN 2004
- TLSA 2013
- Country
- ELDN United States
- TLSA United Kingdom
- Employees
- ELDN N/A
- TLSA N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- TLSA Health Care
- Exchange
- ELDN Nasdaq
- TLSA Nasdaq
- Market Cap
- ELDN 178.4M
- TLSA 187.0M
- IPO Year
- ELDN N/A
- TLSA 2000
- Fundamental
- Price
- ELDN $3.67
- TLSA $1.65
- Analyst Decision
- ELDN Strong Buy
- TLSA
- Analyst Count
- ELDN 2
- TLSA 0
- Target Price
- ELDN $12.50
- TLSA N/A
- AVG Volume (30 Days)
- ELDN 849.2K
- TLSA 190.6K
- Earning Date
- ELDN 08-18-2025
- TLSA 07-29-2025
- Dividend Yield
- ELDN N/A
- TLSA N/A
- EPS Growth
- ELDN N/A
- TLSA N/A
- EPS
- ELDN N/A
- TLSA N/A
- Revenue
- ELDN N/A
- TLSA N/A
- Revenue This Year
- ELDN N/A
- TLSA N/A
- Revenue Next Year
- ELDN N/A
- TLSA N/A
- P/E Ratio
- ELDN N/A
- TLSA N/A
- Revenue Growth
- ELDN N/A
- TLSA N/A
- 52 Week Low
- ELDN $2.38
- TLSA $0.63
- 52 Week High
- ELDN $5.54
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- ELDN 67.56
- TLSA 60.54
- Support Level
- ELDN $3.64
- TLSA $1.43
- Resistance Level
- ELDN $3.93
- TLSA $1.81
- Average True Range (ATR)
- ELDN 0.23
- TLSA 0.07
- MACD
- ELDN 0.05
- TLSA 0.01
- Stochastic Oscillator
- ELDN 71.91
- TLSA 87.50
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.